Novartis Q4 Results
↓
Content
Click below to navigate
through the document
iptacopan - CFB inhibitor
↑
Company overview
Financial review
Conclusions
Appendix
Innovation: Pipeline overview
Financial performance
Innovation: Clinical trials
Cardiovascular, Renal
and Metabolic
Immunology
Neuroscience
> Oncology
Other
Global Health
Abbreviations
NCT04889430 APPELHUS (CLNP023F12301)
Atypical haemolytic uraemic syndrome
Phase 3
Indication
Phase
Patients
50
Primary
Outcome
Measures
Arms
Intervention
Target Patients
Percentage of participants with complete TMA response without the use of PE/PI
and anti-C5 antibody
Single arm open-label with 50 adult patients receiving 200mg oral twice daily
doses of iptacopan
Adult patients with aHUS who are treatment naive to complement inhibitor therapy
(including anti-C5 antibody)
Readout
Milestone(s)
2026
Publication
TBD
References
□ NOVARTIS Reimagining Medicine
Novartis Q4 Results | January 31, 2024
72View entire presentation